Edifice Health, a San Mateo, CA-based immunological health and personalized nutrition company, raised $12m in funding.
The round was led by Leaps by Bayer with participation from Paladin Capital Group, Vertical Venture Partners, Ahren Innovation Capital, Ataraxia Capital Partners, Shanda Grab Ventures, Alafi Capital, and Taisho Pharmaceutical. Seed stage investors include Human Longevity and Performance Impact Venture Fund, Longevity Incubator Fund, Summer Venture Capital, Carlyle Global Advisors, M4 Capital GmbH, and Better Food Ventures.
Leaps by Bayer’s Naveen Krishnan, MD, MPhil, and Paladin Group’s Paul Conley, PhD, will join Edifice’s Board of Directors, alongside Santosh Padki, a San Francisco-based consumer products veteran, and David Furman, PhD, Edifice Founder, Leader of the Stanford Project, and Associate Professor of Applied Artificial Intelligence in Systems and Computational Immunology of Aging at the Buck Institute for Research on Aging.
The company intends to use the funds to grow its foundation of immunological science and add additional talent.
Led by Wolfgang Daum, PhD, Chairman and CEO, and a serial life science entrepreneur, Edifice uses novel proteomic approaches and combines them with proprietary artificial intelligence and predictive analysis to measure the rate at which an individual’s body ages. The company has created a metric to measure systemic chronic inflammation, which, the Stanford Project research showed to be the root cause – and thus, the predictor – of multiple chronic diseases of aging. Furthermore, the company has identified interventional supplements, which can be targeted to an individual’s immunotype to improve inflammatory health and facilitate healthy aging.
Edifice was born out of the Stanford 1,000 Immunomes’ Project, following the 10-year National Institute of Health-funded research in immunological health and aging at Stanford University.